kynurenic acid has been researched along with Neurodegenerative Diseases in 17 studies
Kynurenic Acid: A broad-spectrum excitatory amino acid antagonist used as a research tool.
kynurenic acid : A quinolinemonocarboxylic acid that is quinoline-2-carboxylic acid substituted by a hydroxy group at C-4.
Neurodegenerative Diseases: Hereditary and sporadic conditions which are characterized by progressive nervous system dysfunction. These disorders are often associated with atrophy of the affected central or peripheral nervous system structures.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Here, we review evidence implicating kynurenic acid in the efficacy of ketogenic diet in eye diseases associated with neurodegeneration." | 4.95 | Kynurenic Acid and Neuroprotective Activity of the Ketogenic Diet in the Eye. ( Gasior, M; Jozwiak, K; Mitosek-Szewczyk, K; Tulidowicz-Bielak, M; Turski, WA; Wnorowski, A; Zarnowska, I; Zarnowski, T, 2017) |
| "Boosting KYNA levels, through interference with the KP enzymes or through application of prodrugs/analogs with high bioavailability and potency, is a promising clinical approach." | 2.82 | Kynurenic acid in neurodegenerative disorders-unique neuroprotection or double-edged sword? ( Ostapiuk, A; Urbanska, EM, 2022) |
| "Kynurenic acid (KYNA) is an endogenous neuroprotective agent of increasing importance." | 2.72 | KYNA Derivatives with Modified Skeleton; Hydroxyquinolines with Potential Neuroprotective Effect. ( Lőrinczi, B; Szatmári, I, 2021) |
| "The incidence of neurodegenerative diseases has increased greatly worldwide due to the rise in life expectancy." | 2.72 | Natural Molecules and Neuroprotection: Kynurenic Acid, Pantethine and α-Lipoic Acid. ( Cseh, EK; Tóth, F; Vécsei, L, 2021) |
| "Though migraine and neurodegenerative disorders have a high socioeconomic impact, their therapeutic management has not been fully addressed." | 2.52 | Novel kynurenic acid analogues in the treatment of migraine and neurodegenerative disorders: preclinical studies and pharmaceutical design. ( Csati, A; Fulop, F; Majlath, Z; Szok, D; Tajti, J; Toldi, J; Vecsei, L, 2015) |
| "Kynurenic acid (KYNA) is an endogenous molecule, which is a non-selective antagonist of ionotropic glutamate receptors and has been found to have neuroprotective activity." | 1.91 | Convenient One-Pot Synthesis of Kynurenic Acid Ethyl Ester and Exploration to Direct Synthesis of Neuroprotective Kynurenic Acid and Amide Derivatives. ( Ambatwar, R; Datusalia, AK; Khatik, GL; Verma, S, 2023) |
| "Methylene blue (MB), has been shown to modulate aggregation of amyloidogenic disease proteins." | 1.38 | Methylene blue modulates huntingtin aggregation intermediates and is protective in Huntington's disease models. ( Agrawal, N; Aron, R; Finkbeiner, S; Glabe, C; Lau, A; Lotz, GP; Marsh, JL; Muchowski, PJ; Necula, M; Sontag, EM; Thompson, LM; Tran, A; Yang, G, 2012) |
| "L-kynurenine (L-KYN) serves as a substrate for the synthesis of neurotoxic 3-OH-kynurenine (3-OH-KYN) and neuroprotective kynurenic acid (KYNA)." | 1.30 | Kynurenine metabolism in Alzheimer's disease. ( Baran, H; Deecke, L; Jellinger, K, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (5.88) | 18.2507 |
| 2000's | 3 (17.65) | 29.6817 |
| 2010's | 7 (41.18) | 24.3611 |
| 2020's | 6 (35.29) | 2.80 |
| Authors | Studies |
|---|---|
| Lőrinczi, B | 1 |
| Szatmári, I | 2 |
| Ostapiuk, A | 1 |
| Urbanska, EM | 1 |
| Majerova, P | 1 |
| Olesova, D | 1 |
| Golisova, G | 1 |
| Buralova, M | 1 |
| Michalicova, A | 1 |
| Vegh, J | 1 |
| Piestansky, J | 1 |
| Bhide, M | 1 |
| Hanes, J | 1 |
| Kovac, A | 1 |
| Chen, Y | 1 |
| Zhang, J | 1 |
| Yang, Y | 1 |
| Xiang, K | 1 |
| Li, H | 1 |
| Sun, D | 1 |
| Chen, L | 1 |
| Verma, S | 1 |
| Ambatwar, R | 1 |
| Datusalia, AK | 1 |
| Khatik, GL | 1 |
| Tóth, F | 1 |
| Cseh, EK | 1 |
| Vécsei, L | 6 |
| Zarnowski, T | 1 |
| Tulidowicz-Bielak, M | 1 |
| Zarnowska, I | 1 |
| Mitosek-Szewczyk, K | 1 |
| Wnorowski, A | 1 |
| Jozwiak, K | 1 |
| Gasior, M | 1 |
| Turski, WA | 1 |
| Tajti, J | 1 |
| Majlath, Z | 1 |
| Szok, D | 1 |
| Csati, A | 1 |
| Toldi, J | 3 |
| Fulop, F | 3 |
| Sun, G | 1 |
| Nematollahi, A | 1 |
| Nadvi, NA | 1 |
| Kwan, AH | 1 |
| Jeffries, CM | 1 |
| Church, WB | 1 |
| Rákóczi, K | 1 |
| Klivényi, P | 2 |
| Zádori, D | 2 |
| Vámos, E | 3 |
| Sontag, EM | 1 |
| Lotz, GP | 1 |
| Agrawal, N | 1 |
| Tran, A | 1 |
| Aron, R | 1 |
| Yang, G | 1 |
| Necula, M | 1 |
| Lau, A | 1 |
| Finkbeiner, S | 1 |
| Glabe, C | 1 |
| Marsh, JL | 1 |
| Muchowski, PJ | 1 |
| Thompson, LM | 1 |
| Tan, L | 2 |
| Yu, JT | 1 |
| Plangar, I | 1 |
| Szalardy, L | 1 |
| Baran, H | 1 |
| Jellinger, K | 1 |
| Deecke, L | 1 |
10 reviews available for kynurenic acid and Neurodegenerative Diseases
| Article | Year |
|---|---|
KYNA Derivatives with Modified Skeleton; Hydroxyquinolines with Potential Neuroprotective Effect.
Topics: Animals; Humans; Hydroxyquinolines; Kynurenic Acid; Neurodegenerative Diseases; Neuroprotective Agen | 2021 |
Kynurenic acid in neurodegenerative disorders-unique neuroprotection or double-edged sword?
Topics: Alzheimer Disease; Animals; Brain; Excitatory Amino Acid Antagonists; Humans; Huntington Disease; Ky | 2022 |
Kynurenine-3-monooxygenase (KMO): From its biological functions to therapeutic effect in diseases progression.
Topics: Disease Progression; Humans; Kynurenic Acid; Kynurenine; Kynurenine 3-Monooxygenase; Neurodegenerati | 2022 |
Natural Molecules and Neuroprotection: Kynurenic Acid, Pantethine and α-Lipoic Acid.
Topics: Animals; Antioxidants; Humans; Kynurenic Acid; Metabolic Networks and Pathways; Neurodegenerative Di | 2021 |
Kynurenic Acid and Neuroprotective Activity of the Ketogenic Diet in the Eye.
Topics: Animals; Brain; Diet, Ketogenic; Eye; Eye Diseases; Humans; Ketone Bodies; Kynurenic Acid; Neurodege | 2017 |
Novel kynurenic acid analogues in the treatment of migraine and neurodegenerative disorders: preclinical studies and pharmaceutical design.
Topics: Drug Design; Humans; Kynurenic Acid; Migraine Disorders; Molecular Structure; Neurodegenerative Dise | 2015 |
[Neuroprotection in Parkinson's disease and other neurodegenerative disorders: preclinical and clinical findings].
Topics: Animals; Creatine; Dopamine Agonists; Glatiramer Acetate; Humans; Indans; Kynurenic Acid; Micronutri | 2009 |
Kynurenines in chronic neurodegenerative disorders: future therapeutic strategies.
Topics: Animals; Brain; Glutamic Acid; Humans; Kynurenic Acid; Mitochondrial Diseases; NAD; Neurodegenerativ | 2009 |
Syntheses, transformations and pharmaceutical applications of kynurenic acid derivatives.
Topics: Diabetes Mellitus; Humans; Ischemia; Kynurenic Acid; Neurodegenerative Diseases; Renal Insufficiency | 2009 |
The kynurenine pathway in neurodegenerative diseases: mechanistic and therapeutic considerations.
Topics: Aging; Alzheimer Disease; Amyotrophic Lateral Sclerosis; Animals; Enzyme Inhibitors; Humans; Hunting | 2012 |
7 other studies available for kynurenic acid and Neurodegenerative Diseases
| Article | Year |
|---|---|
Analog of kynurenic acid decreases tau pathology by modulating astrogliosis in rat model for tauopathy.
Topics: Animals; Gliosis; Kynurenic Acid; Kynurenine; Neurodegenerative Diseases; Neuroprotective Agents; Ra | 2022 |
Convenient One-Pot Synthesis of Kynurenic Acid Ethyl Ester and Exploration to Direct Synthesis of Neuroprotective Kynurenic Acid and Amide Derivatives.
Topics: Amides; Humans; Kynurenic Acid; Neurodegenerative Diseases | 2023 |
Expression, purification and crystallization of human kynurenine aminotransferase 2 exploiting a highly optimized codon set.
Topics: Chromatography, High Pressure Liquid; Codon; Escherichia coli; Gene Expression Regulation, Enzymolog | 2016 |
Protective compounds in animal models of trigeminal activation and neurodegeneration.
Topics: Animals; Behavior, Animal; Disease Models, Animal; Drug Administration Schedule; Drug Therapy, Combi | 2012 |
Methylene blue modulates huntingtin aggregation intermediates and is protective in Huntington's disease models.
Topics: Analysis of Variance; Animals; Brain-Derived Neurotrophic Factor; Cells, Cultured; Cerebral Cortex; | 2012 |
Manipulation with kynurenines: a possible tool for treating neurodegenerative diseases?
Topics: Animals; Drug Design; Humans; Kynurenic Acid; Kynurenine; Neurodegenerative Diseases; Quinolinic Aci | 2012 |
Kynurenine metabolism in Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Brain; Caudate Nucleus; Female; Humans; Kinetics; Kynure | 1999 |